

DAFTAR PUSTAKA

1. GLOBOCAN (2018). Latest Global Cancer Data: Cancer Burden Rise to 18,1 Million New cases and 9,6 Million Cancer Deaths in 2018. <https://www.who.int/cancer/PRGlobocanFinal.pdf> - Diakses Februari 2020
2. Wang,S. Liu, S. Air Polution and Lung Cancer Risk. Encyclopedia of environment 2th, Elsevier 2019; 1
3. Depkes. (2015). Infodatin pusat data dan informasi kementerian kesehatan RI:Situasi penyakit kanker di Indonesia. http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin_kanker.pdf - Diakses 12 April 2020
4. American Cancer Society. *Cancer Facts & Figures 2020*. Atlanta: American Cancer Society; 2020. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf>- Diakses Februari 2020
5. J.J. Ko, R. Tudor, H. Li, et al. Reasons for Lack of Referral to Medical Oncology for Systemic Therapy in Stage IV Non-Small-cell lung cancer: comparison of 2003-2006 with 2010-2011, Curr. Oncol. (Toronto, Ont.) 24. 2017; 486
6. Oemiati,R. Rahajeng, E. Kristanto AY. Di Indonesia penyakit. Bulan Penelitian Kesehatan 2011; 190–204.
7. Ananda RR, Ermayanti S, Adiana. Hubungan Staging Kanker Paru dengan Skala Nyeri pada Pasien Kanker PARu yang Dirawat di Bagian Paru RSUP DR M Djamil Padang. 2018;3
8. S. Lefresne, R. Olson, R. Cashman, et al., Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic, Lung Cancer 112. 2017; 35–40.
9. A. Khakwani, A.L. Rich, L.J. Tata, et al., Small-cell lung Cancer in England: trends in survival and chemotherapy using the national lung cancer audit, PLoS One 9. 2014; 89
10. J. Ko, R. Tudor, H. Li, et al. Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer:

- comparison of 2003-2006 with 2010-2011, *Curr. Oncol.* (Toronto, Ont.) 24. 2017; 486
11. S. Iyer, A. Roughley, A. Rider, G. Taylor-Stokes. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study, *Support. Care Cancer* 22. 2014; 181–87
 12. S. Lefresne, R. Olson, R. Cashman, et al. Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic, *Lung Cancer* 112. 2017; 35–40.
 13. Fraser, I. Lefresne, S. Regan, J. Berthelet, E. Chookback, N. Ho, C. Olson, R. Palliative Thoracic Radiotherapy Near The end Of Life In Lung Cancer: Population-Based Analysis, *Lung Cancer* 98. 2019; 97-103
 14. Nieder, C. Tollali, T. Yobuta, S, et al. palliative Thoracic Radiation for Lung Cancer: What is the Impact Dose on Survival?. *J Clin Med Res.* 2017; 482-487
 15. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 394–424.
 16. America Cancer Facts & Figure 4th Edition. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-4th-edition.pdf>. Diakses Februari 2020
 17. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). *SEER Cancer Statistics Review, 1975-2016*, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019 – Diakses Februari 2020
 18. Walasek, T. Reinfus, M. et al. Palliative Thoracic Radiotherapy for Patient with Advance Non-Small Cell Lung Cancer and Poor Performance Status. *Lung Cancer.* 2015; 130-35

19. Herbst RS, Heymach JV, Lippman SM. Lung cancer. *N Engl J Med* 2015;1367–80.
20. Dela Cruz CS, Tanoue LT, Matthany RA. Lung cancer: epidemiology and carcinogenesis. In: Shields TW, editor. *General thoracic surgery*. 7th edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2015; 1281–98
21. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. *Br J Cancer* 2014; 825–33
22. Oorok S, Hegedus B, Laszlo V, et al. Lung cancer in never smokers. *Future Oncol* 2011; 1195–211
23. Kristeleit H, Enting D, Lai R. Basic science of lung cancer. *Eur J Cancer* 2011;47(S319–21
24. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Sci Transl Med* 2010;2:62-93
25. Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). *SEER Cancer Statistics Review, 1975-2016*. 2019; https://seer.cancer.gov/csr/1975_2016/- Diakses Mei 2020
26. Breet, C. Bade, MD. Charles, S. Dela, MD. *Epidemiology, Etiology, and Prvention*. 2020; 865 (863-876)
27. Patel JD. Lung cancer in women. *J Clin Oncol* 2005; 23:3212–8
28. NHIS (2017). *Adult Tobacco Use Information*. https://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm. Diakses 4 Agustus 2020
29. Hoffmann I, Hoffmann D. The changing cigarette: chemical studies and bioassays. In: Boyle P, Gray N, Henningfield JE, et al, editors. *Tobacco: science, policy and public health*. New York: Oxford University Press; 2010. p. 93–126
30. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. *Chem Res Toxicol* 1998;11:559–603

31. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin* 2011;61:212–36.
32. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin* 2019;69(1):7–34.
33. Gnagnarella P, Caini S, Maisonneuve P, et al. Carcinogenicity of high consumption of meat and lung cancer risk among non-smokers: a comprehensive meta-analysis. *Nutr Cancer* 2018;70(1):1–13.
34. Jacobs EJ, Newton CC, Thun MJ, et al. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. *Cancer Res* 2011;71(5):1763–71
35. Brenner DR, Fehringer G, Zhang ZF, et al. Alcohol consumption and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium and the SYNERGY study. *Cancer Epidemiol* 2019; 58:25–32.
36. Xie Y, Qin J, Nan G, et al. Coffee consumption and the risk of lung cancer: an updated meta-analysis of epidemiological studies. *Eur J Clin Nutr* 2016; 70(2):199–206
37. Turner MC, Chen Y, Krewski D, et al. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. *Am J Respir Crit Care Med* 2007; 176(3):285–90.
38. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. *J Clin Oncol* 2006;24(33):5216–22
39. Antoniou KM, Tomassetti S, Tsitoura E, et al. Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. *Curr Opin Pulm Med* 2015;21(6):626–33.
40. Khan S, Imran A, Khan AA, et al. Systems Biology approaches for the prediction of possible role of *Chlamydia pneumoniae* proteins in the etiology of lung cancer. *PLoS One* 2016;11(2)

41. Yu YH, Liao CC, Hsu WH, et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. *J Thorac Oncol* 2011;6(1):32–7
42. Hong S, Mok Y, Jeon C, et al. Tuberculosis, smoking and risk for lung cancer incidence and mortality. *Int J Cancer* 2016;139(11):2447–55.
43. Morris A, Crothers K, Beck JM, et al. An official ATS workshop report: emerging issues and current controversies in HIV-associated pulmonary diseases. *Proc Am Thorac Soc* 2011;8(1):17–26
44. Reddy KP, Kong CY, Hyle EP, et al. Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States. *JAMA Intern Med* 2017;177(11):1613–21
45. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. *AIDS* 2012;26(8):1017–25.
46. Sigel K, Wisnivesky J, Crothers K, et al. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. *Lancet HIV* 2017;4(2):e67–73.
47. Kim AS, Ko HJ, Kwon JH, et al. Exposure to secondhand smoke and risk of cancer in never smokers: a meta-analysis of epidemiologic studies. *Int J Environ Res Public Health* 2018;15(9)
48. Li J, Li WX, Bai C, et al. Particulate matter-induced epigenetic changes and lung cancer. *Clin Respir J* 2017;11(5):539–46.
49. Pope CA, Burnett RT, Thun MJ, et al. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. *JAMA* 2002;287(9): 1132–41
50. Alavanja MC. Biologic damage resulting from exposure to tobacco smoke and from radon: implication for preventive interventions. *Oncogene* 2002;21: 7365–75.
51. A citizens guide radon. United States Environmental Protection Agency. Available at: <http://www.epa.gov/radon/pdfs/citizensguide.pdf> -diakses Mei 2020
52. Jemal A, Bray F, Center MM, et al. Global cancer statistics. *CA Cancer J Clin* 2011;61(2):69–90.

53. Kleinerman RA, Wang Z, Wang L, et al. Lung cancer and indoor exposure to coal and biomass in rural China. *J Occup Environ Med* 2002;44(4)
54. Hosgood HD, Boffetta P, Greenland S, et al. Inhome coal and wood use and lung cancer risk: a pooled analysis of the International Lung Cancer Consortium. *Environ Health Perspect* 2010; 118(12):1743–7.
55. Fingerhut M, Nelson DI, Driscoll T, et al. The contribution of occupational risks to the global burden of disease: summary and next steps. *Med Lav* 2006; 97(2):313–21.
56. Steenland K, Burnett C, Lalich N, et al. Dying for work: the magnitude of US mortality from selected causes of death associated with occupation. *Am J Ind Med* 2003;43(5):41–82
57. Jones RN, Hughes JM, Weill H. Asbestos exposure, asbestosis, and asbestos-attributable lung cancer. *Thorax* 1996;51:9–15.
58. Rivera PM, Mehta AC, Wahidi MM. Diagnosis and management of lung cancer, 3rd ed: American college of physicians evidence-based clinical practice guidelines. *Chest* 2014; 143(5): 142 – 65
59. Horn, L. Lovly, MC. Johnson, DH. Neoplasma of the Lung. *Harrisons Pulmonary and Critical Care Medicine* 3rd ed. 2017; 263-69
60. Horn, Leora. Lovly MC. Neoplasma of the Lung. *Harrison Principales of Internal Medicine* 20th ed. 2018; 517-55
61. O’Callaghan, D. O’Chonnell, F. Lung Cancer. 2017; 481-482: (477-484)
62. Kumar, V. Abbas, KA. Aster, CJ. Lung Tumor. *Robbins Basic Pathology* 10th ed. 2018; 537-40
63. Miranda, B. Ling, L. Daborah, S, et all. Palliative Radiation and Fraction in Medicare Pasiient with Incurable Non-Small Cell Lung Cancer. *Advance in Radiation Oncology*. 2018; (5): 1-23
64. Dwikuntan, L. Rima, A. Hendrik. Eksternal Beam Radation Therapy pada Kanker Paru. *Berkala Ilmiah Kedokteran Duta Wacana*. 2017; 385-388: 375-92
65. Johnstnone, C. Lutz, S. Lung and Central Airway Malignancies. *Handbook of Palliative Radiation Therapy*. 2017; 119-39

66. Cai, J. Chang, J. Yin, FF. Contouring/Delineation of Target Volumes and Critical Structur. *Principals and Practice of Image-Guide Radiation Therapy of Lung Cancer*. 2018; 44-58
67. Yadav, R. Pandya, AR. Palliative Thoracic Radiotherapy for Lung Cancer: What Is the Most Appropriate Fractionation?. 2019; 585
68. Albert AJ, Ford JG, Samet JM. Epidemiology of Lung Cancer. ACCP evidence-based clinical practice guidelines (3th edition). 2015: 30
69. Kara P, Ugur C, Demirkasimoglu T, *at all*. Palliative Radiation Therapy in Lung Cancer with Superior Vena Cava Syndrome. 2011: 538
70. Houston KA, Henley SJ, Li J, White MC, Ricard TB. Pattern in Lung Cancer Incidence Rate and Trends by Histologic Type in United States 2004-2009. 2018:22
71. Mengxi D, Qian W, Nan W, Xiaoguang X, Shijun L. Effect of DNA methylation Inhibitor on RASSF1A genes expression in Non-Small Cell Lung Cancer Cell Line A549 and A549DDP. *Cancer Cell International*. 2013;1
72. Jeong WL, Jong HL, Hoon KY, Byoung YS, Ho JA, sung HK. The Efficacy of External Beam Radiotherapy for Airway Obstruction in Lung Cancer Patients. *Cancer Res Treat*. 2015; 191
73. Bruse S, Hans P, Weissfeld J, Picchi M, Willink R, Do K. Increase Methylation of Lung Cancer-Associated Genes in Sputum DNA of Former Smoker with Chronic Mucous Hypersecretion . *Respiratory Research*. 2014; 8-9
74. Frank, SM. Noroxe, SD, et all. Fractionated Palliative Thoracic Radiotherapy in Non Small Cell Lung Carsinoma – Futile or Worth – While?. *BMC Paliative Care*. 2018; 7
75. Walasek T, Korczynska BS, Dabrowski T, Reinfuss M, Jakubowicz J. Palliative Thoracic Radiotherapy for Patients with Advance Non-Small Cell Lung Cancer and Poor Performance Status. *Lung Cancer*. 2015; 133-134
76. Maclennan K, Campbell S, Little F, Erridge S, Evans T, Price A. Palliative Thoracic Radiotherapy in Locally Advanced/ Metastatic Non-Small Cell

- Lung Cancer. Annual British Thoracic Oncology Group Conference. 2016; 53
77. Ampil P, Chan J, Linden K, McGrath C, Renaud j, Doerin P, Asmis T. Time to Diagnosis and Treatment with Palliative Radiotherapy among Inuit Patients with Cancer from the Arctic Territory of Nunavut Canada. *Clinical Oncology*. 2019; 3
78. Bulbu y, Ozlu T, Arinc S, Ozyurek BA, Gunbatar H, Bahadir A, Ozcelik M. Assessment of Palliative Care in Lung Cancer Turkey. 2016; 51
79. Reinfuss M, Malecka AM, Walasek T, Blecharz P, Jakubowicz J, Skontnicki P. Palliative Thoracic Radiotherapy in Non Small Xell Lung Cancer. An Analysis of 1250 Patients. Palliation of Symptoms, Tolerance and Toxicity. *Lung Cancer*; 2011; 5
80. Su, K. Milano, Mt, et all. Split-Course palliative Radiotherapy for Advanced Non Small Cell Lung Carsinoma. *Journal of Thoracic Oncology*. 2010 ; 187-88
81. ChairM, Amin Z, Sutandyo N, Rachman A, Nugroho P. Karakteristik da Kesintasan 90 Hari Pasien Sindrom Vena Kave Superior di Rumah Sakit Cipto Mangunkusumo dan Rumah Sakit Kanker Dharmais. *Indonesia Journal of Chest*.2014; 29
82. Tri A, Munandar A. Peran Radioterapi dan Tatalaksana Umum pada Sindrom Vena Kava Superior. *Radioterapi dan Onkologi Indonesia*. 2019; 61-2
83. Clement ZA, luu M, Bibault JE, Daveau C, Kreps S, Jaulmes H, Dessard Diana B. Effective delivery of Palliative Radiotherapy: A Prospective study. 2018; 367